Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4912-4925

  Catto, Marco ^a   Nicolotti, Orazio ^a   Leonetti, Francesco ^a   Carotti, Andrea ^a   Favia, Angelo Danilo ^a   Soto Otero, Ramón ^b   Méndez Álvarez, Estefanía ^b   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROFAROMINE; CLORGYLINE; COUMARIN DERIVATIVE; IPRONIAZID; LAZABEMIDE; LIGAND; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENYL GROUP; RASAGILINE; SELEGILINE; TOLOXATONE; TRANYLCYPROMINE;

ARTICLE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; ENZYME INHIBITION; IC 50; MODEL; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION ANALYSIS;

ANIMALS; BINDING SITES; COUMARINS; ISOENZYMES; LIGANDS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; STEREOISOMERISM;

EID: 33746933809     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060183l     Document Type: Article

References (56)

1. Tipton, K. F. Enzymology of monoamine oxidase. Cell Biochem. Funct. 1986, 4, 79-87.
2. Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J. Biol. Chem. 2001, 276, 9877-9882.
3. Johnston, J. P. Some observation upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 1968, 17, 1285-1297.
4. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue distribution of human monoamine oxidase-A and oxidase-B messenger-Rna. J. Neurochem. 1990, 55, 1166-1169.
5. Fowler, C. J.; Ross, S. B. Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological and clinical properties. Med. Res. Rev. 1984, 4, 323-358.
6. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: Safety and future. Neurotoxicology 2004, 25, 215-221.
7. Kyburz, E. New developments in the field of MAO inhibitors. Drug News Perspect. 1990, 3, 592-599.
8. Drukarch, B.; van Muiswinkel, F. L. Drug treatment of Parkinson's disease. Time for phase II. Biochem. Pharmacol. 2000, 59, 1023-1031.
9. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 25, 271-277.
10. (a) Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2002, 9, 22-26.
11. (b) Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750-9755.
12. Ma, J. C.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Biol. 2004, 338, 103-114.
13. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12684-12689.
14. Novaroli, L.; Reist, M.; Favre, E.; Carotti, A.; Catto, M.; Carrupt, P. A. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg. Med. Chem. 2005, 13, 6212-6217.
15. Geha, R. M.; Chen, K.; Shih, J. C. Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat. J. Neurochem. 2000, 75, 1304-1309.
16. Novaroli, L. Rational strategy and screening methods to identify multifunctional hits for the treatment of PD and AD. Ph.D. Thesis, No. 3643, Université de Genève, Faculté des Sciences, 2005.
17. Altomare, C.; Carrupt, P. A.; Gaillard, P.; El Tayar, N.; Testa, B.; Carotti, A. Quantitative structure metabolism relationship analyses of Mao-mediated toxication of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and analogs. Chem. Res. Toxicol. 1992, 5, 366-375.
18. (a) Kneubuhler, S.; Carta, V.; Altomare, C.; Carotti, A.; Testa, B. Synthesis and monoamine-oxidase inhibitory activity of 3-substituted 5H-indeno[1,2-c]pyridazines. Helv. Chim. Acta 1993, 76, 1956-1963.
19. (b) Kneubuhler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P. A.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase-B by 5H-indeno[1,2-c]pyridazines. Biological activities, quantitative structure-activity-relationships (QSARs) and 3D-QSARs. J. Med. Chem. 1995, 38, 3874-3883.
20. (c) Altomare, C.; Cellamare, S.; Summo, L.; Catto, M.; Carotti, A.; Thull, U.; Carrupt, P. A.; Testa, B.; Stoeckli-Evans, H. Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: effects of lipophilicity and structure-activity relationships. J. Med. Chem. 1998, 41, 3812-3820.
21. (d) Thull, U.; Kneubuhler, S.; Gaillard, P.; Carrupt, P. A.; Testa, B.; Altomare, C.; Carotti, A.; Jenner, P.; Mcnaught, K. S. P. Inhibition of monoamine-oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity-relationships. Biochem. Pharmacol. 1995, 50, 869-877.
22. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, B.; Gnerre, C.; Carotti, A.; Carrupt, P. A.; Testa, B. Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies. Bioorg. Med. Chem. Lett. 2002, 12, 3551-3555.
23. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P. A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: Biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 2000, 43, 4747-4758.
24. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity plays a major role in modulating monoamine oxidase B (MAO-B) inhibition by 7-substituted coumarins. Chem. Biodiversity 2006, 3, 134-144.
25. Bruhlmann, C.; Ooms, F.; Carrupt, P. A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarin derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 2001, 44, 3195-3198.
26. Atkins, R. L.; Bliss, D. E. Substituted coumarins and azacoumarins. Synthesis and fluorescent properties. J. Org. Chem. 1978, 43, 1975-1980.
27. Rendenbach-Müller, B.; Schlecker, R.; Traut, M.; Weifenbach, H. Synthesis of coumarins as subtype-selective inhibitors of monoamine-oxidase. Bioorg. Med. Chem. Lett. 1994, 4, 1195-1198.
28. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
29. SYBYL, version 7.1; Tripos Inc. (1699 South Hanley Road, St. Louis, MO 63144).
30. Gaillard, P.; Carrupt, P. A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D QSAR. Methods and applications. J. Comput.-Aided Mol. Des. 1994, 8, 83-96.
31. Dunn, W. J., III; Wold, S.; Edlund, U.; Hellberg, S.; Gasteiger, J. Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: the PLS method. Quant. Struct.-Act. Relat. 1984, 3, 131-137.
32. Baroni, M.; Costantino, G.; Cruciani, G.; Riganelli, D.; Valigi, R.; Clementi, S. Generating optimal linear PLS estimations (GOLPE): an advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. 1993, 12, 9-20.
33. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modelling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
34. Thompson, J. D.; Gibson, T. J.; Plewniak, F.; Jeanmougin, F.; Higgins, D. G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997, 24, 4876-4882.
35. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
36. Schulz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model. 2003, 9, 47-57.
37. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287-2303.
38. Kellenberger, E.; Rodrigo, J.; Muller, P.; Rognan, D. Comparative evaluation of eight docking tools for docking and virtual screening accuracy. Proteins: Struct., Funct., Bioinf. 2004, 57, 225-242.
39. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions. J. Med. Chem., in press.
40. Westhead, D. R.; Clark, D. E.; Murray, C. W. A comparison of heuristic search algorithms for molecular docking. J. Comput.-Aided Mol. Des. 1997, 11, 209-228.
41. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using Gold. Proteins: Struct., Funct., Bioinf. 2003, 52, 609-623.
42. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857.
43. Reist, M.; et al. Unpublished data.
44. Carotti, A.; Leonetti, F.; Stefanachi, A.; Catto, M.; Capaldi, C.; Muncipinto, G.; Pisani, L.; Nicolotti, O. In silico design and focused solid phase synthesis of new, selective enzyme inhibitors with potential in cancer and neurological therapies. Sci. Pharm. 2005, 73, S27.
45. O'Kennedy, R., Thornes, R. D., Eds. Coumarins. Biology, Applications and Mode of Action; John Wiley and Sons: Chichester, U.K., 1997.
46. Rendenbach, B.; Weifenbach, H. Teschendorf, H.-J. Arylalkoxycumarine. Verfahren zu Ihre Herstellung und Diese Enthalende Therapeutische Mittel (Arylalkoxycoumarins. Their Production Procedures and Therapeutics). Patent DE 3834861 Al, 1990 (BASF AG).
47. Schlecker, R.; Schmidt, P.; Thieme, P. C.; Lenke, D.; Teschendorf, H. J.; Traut, M.; Müller, C. D.; Hofmann, J. P.; Kreiskott, H. Neue Sulfonsäureester von Hydroxycumarinen, Ihre Herstellung und Sie Enthaltende Arzneimittel (New Sulfonic Acid Esters of Hydroxycoumarins: Their Production and Medicinal Properties). Patent DE 3243158 Al, 1984 (BASF AG).
48. Ahluwalia, V. K.; Kumar, D.; Gupta, Y. K. Claisen rearrangement of some 7-cinnamyloxybenzo-α-pyrones. Indian J. Chem. 1978, 16B, 579-583.
49. Gia, O.; Uriarte, E.; Zagotto, G.; Baccichetti, F.; Antonello, C.; Marcianimagno, S. Synthesis and photobiological activity of new methylpsoralen derivatives. J. Photochem. Photobiol., B 1992, 14, 95-104.
50. von Pechmann, H. Duisberg, C. Über die verbindungen der phenole mit acetessigäther (On the compounds of phenol with acetoacetate). Chem. Ber. 1883, 16, 2119-2128.
51. Marti-Renom, M. A.; Stuart, A. C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modelling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
52. Laskowski, R. A.; Macarthur, M. W.; Moss, D. S.; Thornton, J. M. Procheck. A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
53. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M. C. SWISS-MODEL: an automated protein homology-modelling server. Nucleic Acids Res. 2003, 31, 3381-3385.
54. Lesk, A. M. Introduction to Protein Science Architecture, Function, and Genomics; Oxford University Press: Oxford, U.K., 2004.
55. Mendez-Alvarez, E.; Soto-Otero, R.; Sanchez-Sellero, I.; Lopez-Rivadulla, L. M.; Lamas, M. Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. Life Sci. 1997, 60, 1719-1727.
56. Soto-Otero, R.; Mendez-Alvarez, E.; Hermida-Ameijeiras, A.; Sanchez-Sellero, I.; Cruz-Landeira, A.; Lamas, M. L. R. Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals. Potential implications in relation to oxidative stress. Life Sci. 2001, 69, 879-889.